Dr. Elaine Jones is an accomplished biopharmaceutical executive with more than 20 years of life science investing experience. She has served on over 35 life science company boards and has both biopharma research and business development expertise.
Dr. Jones currently serves on the boards of the publicly traded companies CytomX (NASDAQ: CTMX), HBM Healthcare Investments AG (SIX: HBMN), and NextCure (NASDAQ: NXTC), and is the Chair of Gritstone bio (NASDAQ:GRTS). In addition, she is Chair of Mironid, a privately held UK company focused on new treatments for degenerative kidney disease and serves as a Director of Myeloid Therapeutics in Cambridge, MA, a private company developing products to reprogram myeloid cells for cancer therapy. She also serves on the advisory board of the Novartis Venture Fund and as a member of the CPRIT Product Development Review Council. Dr. Jones is a graduate of Juniata College, received her Ph.D. in Microbiology from the University of Pittsburgh, and conducted post-doctoral research at the National Institutes of Health.
Until April 2019, Dr. Jones was Vice President, Venture Capital, at Pfizer Ventures (PVI). Prior to Pfizer, she was a General Partner with the venture fund, EuclidSR Partners. Dr. Jones began her investing career in 1999 at S.R. One, GlaxoSmithKline’s corporate fund. Previously, she served as Director, Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D. Dr. Jones is a graduate of Juniata College, received her Ph.D. in Microbiology from the University of Pittsburgh, and conducted post-doctoral research at the National Institutes of Health.Sessions: